(de-news.net) – BioNTech, the biopharmaceutical company headquartered in Mainz, has formally announced its intention to acquire CureVac, a biotechnology firm based in Tübingen, with the objective of advancing research and development in the domain of messenger RNA (mRNA)-based cancer immunotherapies. As part of the acquisition, CureVac shareholders will have the opportunity to exchange their holdings for BioNTech American Depositary Shares through a publicly disclosed transaction mechanism. The valuation of CureVac’s shares stands at approximately 5.46 USD, representing a 55% premium over the volume-weighted average trading price over the preceding three months.
The strategic rationale underpinning the transaction is the convergence of the complementary competencies of both organizations in the design and manufacturing of mRNA-based therapeutics. CureVac’s research and production infrastructure in Tübingen will be integrated into BioNTech’s existing operational framework. The governing bodies of both entities—their respective executive and supervisory boards—have sanctioned the agreement, which is projected to reach finalization within the current fiscal year.
Alexander Zehnder, Chief Executive Officer of CureVac, underscored the alignment of both firms in their commitment to harnessing the potential of mRNA technology. Ugur Sahin, Chief Executive Officer of BioNTech, characterized the acquisition as a pivotal step in advancing the company’s strategic focus on oncological innovation. According to publicly available corporate statements, the transaction enjoys the endorsement of the German federal government, and BioNTech anticipates approval from CureVac’s shareholders, who collectively control 50.08 percent of the company’s outstanding equity.
The acquisition aligns with BioNTech’s overarching objective of augmenting its capacity in the research, development, and production of mRNA-based oncology treatments—a sector in which it has already achieved global prominence through its pioneering work on COVID-19 vaccine development. The two entities share a common vision and have expressed their mutual intent to consolidate expertise to optimize therapeutic advancements. BioNTech has affirmed its commitment to maintaining CureVac’s operational presence in Tübingen as an integral component of the consolidated entity.
